AccuTheranostics
AccuTheranostics, Inc. offers a full line of laboratory tests designed to provide information to tailor treatment to the individual patient’s cancer.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
$60.0k | - | ||
| Total Funding | 000k | ||
Related Content
Founded in 2012 and headquartered in Buffalo, NY, AccuTheranostics, Inc. operates as a clinical medical laboratory focused on personalizing cancer treatment. The company provides services to physicians, specifically oncologists, to aid in the selection of effective chemotherapy regimens for their patients. The business model centers on offering specialized laboratory tests that analyze a patient's own tumor cells to predict their response to various cancer drugs.
The core of AccuTheranostics' service portfolio is a chemosensitivity and chemoresistance assay, which was previously known as ChemoFx® and is now marketed as ChemoFit™. This laboratory test requires a small sample of a patient's solid tumor, obtained through biopsy or surgery. In the lab, these living cancer cells are cultured and then exposed to different chemotherapy agents, both individually and in combination. The assay measures how many cancer cells are killed by each treatment, generating a dose-response curve that classifies the tumor's likely reaction as responsive, intermediate, or non-responsive. This process provides oncologists with a chemo-resistance and sensitivity profile unique to that patient's cancer.
The primary benefit for clinicians is the ability to make more informed treatment decisions, moving away from a one-size-fits-all approach. By identifying which drugs are most likely to be effective and which are likely to be resisted by the tumor, the service aims to improve patient outcomes and avoid the toxicity associated with ineffective therapies. The service can be utilized for various solid tumor types, including primary, recurrent, and metastatic cancers, with a historical focus on gynecologic cancers like ovarian cancer. While PitchBook data from January 2024 lists the company as 'Out of Business', other sources indicate ongoing operations and services.
Keywords: personalized medicine, chemosensitivity testing, oncology diagnostics, cancer treatment, in-vitro assay, clinical laboratory, chemoresistance, solid tumors, gynecologic oncology, therapeutic guidance